REG - Hemogenyx Pharma Plc - Result of Extraordinary General Meeting

Hemogenyx PharmaceuticalsAnnouncement

09/12/2024 13:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241209:nRSI3752Pa&default-theme=true

RNS Number : 3752P  Hemogenyx Pharmaceuticals PLC  09 December 2024

9 December 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Result of Extraordinary General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the
Extraordinary General Meeting ("GM") held earlier today, all resolutions were
duly passed on a show of hands. The numbers of proxy votes for each resolution
submitted prior to the meeting are presented below.

 

Proxy Voting Results

 Ordinary Resolutions                                                            Votes for    % of votes cast for  Votes Against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)   Votes with-held (2)
 1. To grant the Directors with authority to subdivide and reclassify the        518,007,554  95.39                25,041,580     4.61                     543,049,134       38.74%                             1,494,053
 existing ordinary shares.
 2. To grant the Directors with authority to consolidate the New Ordinary        518,772,622  95.41                24,976,512     4.59                     543,749,134       38.79%                             794,053
 Shares.
 3. To grant the Directors authority to allot and issue shares and grant rights  500,896,092  92.24                42,153,042     7.76                     543,049,134       38.74%                             1,494,053
 to subscribe for shares in the Company for the purposes of Section 551 of the
 Act.
 Special Resolutions                                                             Votes for    % of votes cast for  Votes against  % of votes cast against  Total votes cast  Total votes cast as % of ISC (1)   Votes with-held (2)
 4. To approve the adoption of the New Articles.                                 514,762,980  94.80                28,213,641     5.20                     542,976,621       38.73%                             1,566,566
 5. To dis-apply the statutory rights of pre-emption in respect of the           493,949,091  92.78                38,427,061     7.22                     532,376,152       37.98%                             12,167,035
 allotment of equity securities for cash under Section 561(1) of the Act.

 

(1)        The Company's issued share capital ("ISC") on 5 December
2024, being the date on which members had to be entered in the register of
members of the Company in order to be entitled to attend and vote at the
meeting, was 1,401,815,988 ordinary shares.

(2)        A 'vote withheld' in respect of any resolution is not a
vote in law and is not counted in the calculation of the proportion of the
votes for and against it.

 

A copy of the resolutions passed has been submitted to the National Storage
Mechanism and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a pre-clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses as engines
for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMEADANEAPLFFA